NCT06265012View on ClinicalTrials.gov

Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

September 23, 2024

Study Completion Date

September 23, 2024

Conditions

Marburg Virus Disease

Interventions

BIOLOGICAL

PHV01

Marburg virus vaccine

BIOLOGICAL

Placebo

Lactated Ringer's Solution

Trial Locations (1)

33024

CenExel RCA, Hollywood

All Listed Sponsors

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Public Health Vaccines LLC

INDUSTRY

NCT06265012 - Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter